Biotech and Pharmaceuticals Medicine

More

  • boston_scientific.jpg

    Man, it's gotta hurt when the publicly-traded company you've been leading for years announces you're stepping down and investors pop the champagne corks.

  • Rabies in the Americas 2009

    ACC, ADA, AHA, ASCO, ICAD, TCT. That's just a handful of the acronyms and abbreviations for scientific and medical conferences that I've attended over the years. But this year I might be able to add RITA to my dance card. I'd never heard of her (it) before this morning when I got this press release from Crucell, which owns technology for faster, better, cheaper vaccine manufacturing.

  • Apple CEO Steve Jobs introduces the new iPod Nano in San Francisco, Tuesday, Sept. 9, 2008.

    The growing, influential role of Twitter has never been more evident than during the recent Iranian uprising. But did the story that "The Wall Street Journal" broke last Friday night about Apple's Steve Jobs getting a liver transplant actually appear on Twitter first?

  • Healthcare stocks rebound, so is significant reform dead? Healthcare stocks have been moving off their lows since Tuesday and are up significantly today after moving almost straight down in June.

  • Two days after the FDA ordered Matrixx Initiatives' Zicam off the market the story remains one of the most emailed articles on "The New York Times" website. And the company seems to still be trying to find its corporate crisis footing.

  • Zicam

    I was an early adopter of Zicam when it came on the market 10 years ago. Whenever I felt a cold coming on, I'd load up on the stuff along with Vitamin C and zinc lozenges. So, last night I went searching through the bathroom cabinets to find my Zicam stash to toss it in the trash per the FDA's advisory.

  • cadeuses2.jpg

    The r-word has become a rejoinder to anyone who says that this country must reduce its runaway health spending, especially anyone who favors cutting back on treatments that don’t have scientific evidence behind them. You can expect to hear a lot more about rationing as health care becomes the dominant issue in Washington this summer.

  • Lipitor

    I have a confession to make. I try to be as transparent as possible, to share as much information as I can about how the sausage is made. To that end, on at least a few occasions I’ve mentioned on this blog and on CNBC, that I’ve been on 10 milligrams of Lipitor.

  • genentech_slide34.jpg

    This morning the apparently Red Bull-fueled (or maybe he's a Starbucks triple-shot guy) biotech analyst at Deutsche Bank, Dr. Mark Schoenebaum, did a deep dive for clients in a presentation he called, "Getting ready for summer!"

  • Pharma Stocks

    To almost no one's surprise, for the first time in 41 years, the World Health Organization has declared a full-blown swine flu pandemic. But the declaration is tied more to the geographic spread of the virus than it is to its virulence.

  • Medtronic spokesman Steve Cragle sent CNBC this clarification to Mr. Hawkins' answer to Mike Huckman's question regarding the Senate investigation into a doctor who has done consulting work for MDT.

  • Risky Business

    "It's a risky business." I don't think I'll ever forget when a Chief Financial Officer said that at an investor conference last year in lieu of reading the whole boring boilerplate "Safe Harbor Statement."

  • Amylin

    In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.

  • Doctor Writing

    A year or so ago, when customers buttonholed the pharmacists at Almand’s Drug Store here the questions were invariably about dosing or side effects. These days, they are almost always about cost.

  • pharma_new3.jpg

    The cost of drugs was a hot topic at ASCO this year, especially with the release of the big test results combining two very expensive treatments for lung cancer. The study showed using Avastin from Roche and Genentech and a pill, Tarceva, from OSI Pharmaceuticals, Roche and Genentech slowed down progression of the disease by a little more than a month.

  • asco_new_logo.jpg

    I'm happy to report that I'm scribbling out this blog from the air-conditioned comfort of the convention center in Orlando. It's the first time in my six or seven years of covering ASCO that the organization has let CNBC broadcast live from inside. And, guess what? No one seems freaked out about it.

  • GM Bankruptcy

    How will male General Motors retirees get their motor runnin'? Do they start paying for their impotence drugs out of their own pocket? Because apparently, under the new deal the company won't pick up the tab anymore.

  • cadeuses2.jpg

    Consumers may be saving more and spending less, but big pharma is on a shopping spree. And I'm not talking about the really big deals including Roche buying Genentech, Pfizer buying Wyeth and Merck buying Schering-Plough. I'm talking about the two deals that have been done in less than a week between major drug companies and baby biotechs specializing in oncology.

  • Amylin

    I'm juggling the Amylin Pharmaceuticals proxy fight, then ASCO (American Society of Clinical Oncology), then the Biogen Idec shareholder meeting and then the ADA (American Diabetes Association) meeting all within a week-and-a-half.

  • Cougar

    This fall ABC is launching a new show with Courtney Cox called "Cougar Town." Courtney was one of my favorite "Friends" stars and cougars are certainly a hot cultural phenomenon. Could cougars be five minutes ago by the time the show premieres? Perhaps. But maybe ABC has a hit on its hands. New TV shows are always a roll of the dice. And so is Johnson & Johnson's journey into "Cougar Town."